Tuff-Stuff
7 years ago
Board NEEDS Updated><-CYBERONICS, is now LivaNova (LIVN) NASDAQ GS
Stock Quotes and Chart
http://investor.livanova.com/phoenix.zhtml?c=254127&p=irol-stockquote
Intraday High 51.40 52 Week High 63.21
Intraday Low 50.66 52 Week Low 40.84
http://www.nasdaq.com/symbol/livn/premarket
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN.”
LivaNova PLC Announces Its Intent to Delist from London Stock Exchange
LONDON--(BUSINESS WIRE)--Feb. 23, 2017-- LivaNova PLC (NASDAQ: LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced it applied for the voluntary cancellation of its standard listing of ordinary shares with the United Kingdom Listing Authority and to the London Stock Exchange (“LSE”) to cancel trading of those shares. The Company’s decision was primarily due to the low volume of its shares being traded on the LSE. Trading of the Company’s shares on the LSE will cease at the close of business on April 4, with the cancellation expected to become effective at 8 a.m. GMT on April 5.
The Company will continue to serve its shareholders through its listing on the NASDAQ Stock Market (“NASDAQ”), where today the vast majority of trading in LivaNova shares occurs.
The Company is announcing this decision now to provide sufficient time for shareholders who may be unable to hold shares on NASDAQ to liquidate their holdings in an orderly manner. Shareholders may continue to direct their broker to complete a CREST Stock Withdrawal in order for their depository interests to be cancelled and for book-entry interests in respect of the underlying shares to be transferred from the Depository Trust Company (“DTC”) participant account of Computershare to the account of their designated DTC participant.
Shareholders wishing to ask further questions about this process should contact Computershare Investor Services PLC at +44 0370 702 0000 or LivaNova’s Corporate Secretary at Company.Secretariat@LivaNova.com. LivaNova’s corresponding RNS and 8-K filings are available at Investor.LivaNova.com.
About LivaNova
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.),
http://investor.livanova.com/phoenix.zhtml?c=254127&p=irol-newsArticle&ID=2248859
stocktrademan
9 years ago
$CYBX DD Notes ~ http://www.ddnotesmaker.com/CYBX
bullish
good volume
$CYBX recent news/filings
## source: finance.yahoo.com
Thu, 20 Nov 2014 12:18:39 GMT ~ Cyberonics beats 2Q profit forecasts
read full: http://sg.finance.yahoo.com/news/cyberonics-beats-2q-profit-forecasts-121839549.html
*********************************************************
Thu, 20 Nov 2014 12:18:39 GMT ~ Cyberonics beats 2Q profit forecasts
read full: http://finance.yahoo.com/news/cyberonics-beats-2q-profit-forecasts-121839080.html
*********************************************************
Thu, 20 Nov 2014 12:13:00 GMT ~ 7:13 am Cyberonics beats by $0.05, misses on revs; reaffirms FY15 EPS guidance, lowers FY15 revs guidance
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cybx
*********************************************************
Thu, 20 Nov 2014 12:07:03 GMT ~ Q2 2015 Cyberonics Inc Earnings Release - Before Market Open
read full: http://biz.yahoo.com/research/earncal/20141120.html?t=cybx
*********************************************************
Thu, 20 Nov 2014 12:03:34 GMT ~ CYBERONICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/141120/cybx8-k.html
*********************************************************
$CYBX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CYBX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CYBX/company-info
Ticker: $CYBX
OTC Market Place: Not Available
CIK code: 0000864683
Company name: Cyberonics, Inc.
Company website: http://www.cyberonics.com
Incorporated In: DE, USA
$CYBX share structure
## source: otcmarkets.com
Market Value: $1,291,574,190 a/o Nov 19, 2014
Shares Outstanding: 26,624,906 a/o Aug 18, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$CYBX extra dd links
Company name: Cyberonics, Inc.
Company website: http://www.cyberonics.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CYBX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CYBX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CYBX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/news - http://finance.yahoo.com/q/h?s=CYBX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CYBX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CYBX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CYBX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cyberonics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Cyberonics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Cyberonics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cyberonics.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cyberonics.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cyberonics.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CYBX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000864683&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CYBX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CYBX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CYBX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CYBX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CYBX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CYBX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CYBX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CYBX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CYBX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CYBX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CYBX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CYBX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CYBX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CYBX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CYBX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CYBX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CYBX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CYBX
$CYBX DD Notes ~ http://www.ddnotesmaker.com/CYBX
Tuff-Stuff
13 years ago
CYBX Cyberonics Announces FDA Approval of Aspire High Capacity Generator for VNS Therapy
Press Release Source: Cyberonics, Inc. On Tuesday February 1, 2011, 4:46 pm
HOUSTON, Feb. 1, 2011 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq:CYBX - News) today announced that the AspireHC™ (High Capacity) generator for use in vagus nerve stimulation (VNS) therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.
The AspireHC generator (development name NXT HC) represents the fifth generation of VNS Therapy® technology. This product incorporates greater functionality for the benefit of patients and their physicians, including longer battery life, improved electronics and simplified features for programming.
The AspireHC generator is expected to be in limited commercial release in the United States in the Company's current quarter ending April 29, 2011. The company has applied for the CE Mark.
"The AspireHC generator will enhance the quality of life for VNS patients, and we are gratified that the FDA completed their review in an expeditious manner," said Dan Moore, Cyberonics' President and Chief Executive Officer. "In addition, this generator provides an important platform for future new product introductions, including the AspireSR seizure response system for which a European clinical trial is planned to start in the first half of calendar 2011."
To date, more than 60,000 patients worldwide have been implanted with the VNS Therapy System for epilepsy.
About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Safe harbor statement
Tuff-Stuff
14 years ago
>Device Makers May Gain If U.S. Health Plan Fails, JPMorgan Says
Jan. 20 (Bloomberg) -- Volcano Corp. and Wright Medical Group Inc. are among medical device makers that stand to gain if health-care legislation in Congress fails after Republican Scott Brown yesterday won a Senate seat in Massachusetts, according to JPMorgan Chase & Co.
“The companies that are most impacted, and therefore benefit most should the bill collapse, are small-cap, emerging growth companies that are earlier on the profitability curve,” analysts including New York-based Michael Weinstein wrote in a note to clients today.
NuVasive Inc., Thoratec Corp., Integra LifeSciences Holdings Corp. and ev3 Inc. may also benefit, the analysts wrote, as a proposed industry excise tax would no longer present a threat to their earnings. Larger companies like Boston Scientific Corp, CR Bard Inc., Edwards Lifesciences Corp., Stryker Corp., St Jude Medical Inc. and Zimmer Holdings Inc., whose income would be more resilient to the tax, may also get a boost, the analysts said.
Brown’s victory over Democratic state Attorney General Martha Coakley for a seat held by the late Senator Edward M. Kennedy for nearly half a century represents a political upset that imperils President Barack Obama’s efforts to overhaul the U.S. health system and sends a warning to Democrats ahead of November’s midterm elections.
Block Votes
The result boosts Republican Senate numbers to 41, enough to block votes on the health changes, Obama’s top legislative goal. Democratic congressional leaders are negotiating a final version of a health bill that many Democrats view as a tribute to Kennedy’s decades of work on the issue.
The legislation, which would be the most sweeping revamp of the medical system in 45 years, is aimed at extending health coverage to tens of millions of uninsured Americans by expanding the Medicaid program for the poor and setting up online insurance-purchasing exchanges, while curbing costs at the same time.
Shares of health insurers and pharmaceutical companies rose in the U.S. yesterday as investors anticipated a Republican victory in Massachusetts. The Standard & Poor’s 500 Managed Health Care Index, which tracks the top six insurers, gained 3.7 percent, outpacing the S&P 500’s 1.3 percent increase. The S&P 500 Pharmaceuticals Index rose 2.2 percent. Humana Inc. jumped 7.1 percent, while Merck & Co. climbed 2.9 percent, leading gains in the Dow Jones Industrial Average.
Options traders also boosted bullish bets on U.S. health- care stocks on speculation that Republicans will block the overhaul.
“Health-care companies are going to perform better if there’s no government system,” Kevin Nichols, vice president for ETF trading at Newedge Group in New York, said yesterday. The Democrat loss means “the odds increase that the health-care bill will get knocked down.”
Tuff-Stuff
14 years ago
$16.03cl UPah>Cyberonics beats by $0.12, beats on revs; guides FY10 revs in-line~
Cyberonics posts higher Q2 profit, ups FY2010 rev view
Wed Nov 18, 2009 6:18pm ES
* Q2 EPS $1.73 vs yr-ago $0.14
* Q2 rev up 13 pct to $40.7 mln
* Raises FY 2010 rev outlook
* Shares up 5 pct after-market
Nov 18 (Reuters) - Medical-device maker Cyberonics Inc (CYBX.O) posted a higher quarterly profit, helped by strong growth in its epilepsy business and a non-cash tax gain, and raised its full-year 2010 revenue outlook.
For the second quarter ended Oct. 23, the company earned $50.1 million, or $1.73 per share, compared with $8.4 million, or 14 cents a share, in the year-ago period.
Revenue rose to $40.7 million from $36.0 million last year.
Excluding items, the company earned 32 cents a share.
U.S. net product sales attributable to the epilepsy indication rose 16 percent to $33.2 million.
The company recorded a non-cash tax benefit of $40.5 million.
Analysts on average expected earnings of 20 cents a share, excluding special items, on revenue of $39.9 million, according to Thomson Reuters I/B/E/S.
For fiscal 2010, the company now expects revenue of $159 million to $162 million, up from its prior view of $157 million to $161 million.
It now sees income from operations for fiscal 2010 of between $28 million and $30 million, up from the earlier view of $24 million to $27 million.
Shares of the company rose 5 percent to $16.90 in after-market trade. They closed at $16.03 Wednesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Unnikrishnan Nair)
Tuff-Stuff
15 years ago
CYBX Cyberonics fiscal 1Q 2010 profit more than triples
Cyberonics says fiscal first-quarter 2010 profit more than triples as sales rise 14 percent
* On Wednesday August 19, 2009, 8:21 pm EDT
*
Companies:
o Cyberonics Inc.
HOUSTON (AP) -- Medical device maker Cyberonics Inc. said Wednesday that its fiscal first-quarter 2010 profit more than tripled to $7.9 million to top Wall Street expectations as sales rose 14 percent.
The company reiterated its guidance for the remainder of its fiscal year.
The earnings for the quarter ended July 24 totaled 23 cents a share, compared with a year-ago profit of $2.1 million, or 8 cents a share.
Revenue rose to $38.5 million from $33.7 million a year earlier, helped by strong results in its epilepsy unit.
Analysts surveyed by Thomson Reuters, who generally exclude one-time items from their estimates, were expecting first-quarter earnings of 17 cents a share on revenue of $37.3 million.
Going forward, Cyberonics reiterated its outlook for full-year net sales of $157 million to $161 million on a constant currency basis, and continues to expect that income from operations will range between $24 million and $27 million.
Cyberonics shares fell 42 cents, or 2.4 percent, to close the regular trading session at $17.42 before the results were released. In after-market trading, its shares rose 40 cents, or 2.3 percent, to $17.82.
Related Headlines
* Cyberonics fiscal 1Q 2010 profit more than triples - AP
* [video] Clothing Retailers Slip - at Forbes.com
* Movers roundup: ASM International, La-Z-Boy - AP
* CYBERONICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - EDGAR Online
* Cyberonics Reports Strong Fiscal 2010 First Quarter Results - PR Newswire
Tuff-Stuff
15 years ago
CYBX Cyberonics beats by $0.05, beats on revs; reaffirms FY10 revs in-line
Reports Q1 (Jul) earnings of $0.23 per share, $0.05 better than the First Call consensus of $0.18; revenues rose 14.2% year/year to $38.5 mln vs the $37.5 mln consensus. Co reaffirms in-line guidance for FY10, sees FY10 revs of $157-161 mln vs. $159.69 mln consensus; continues to expect that income from operations will be in the range of $24 million to $27 million.
And earlier, got a downgrade
Cyberonics shares drop after downgrade to 'Hold'
Canaccord analyst sees slower patient growth for Cyberonics, downgrades medical device maker
* On Wednesday August 19, 2009, 2:40 pm EDT
o
Buzz up! 0
o Print
*
Companies:
o Cyberonics Inc.
NEW YORK (AP) -- Shares of medical device maker Cyberonics Inc. fell Wednesday after a Canaccord Adams analyst downgraded the company, saying a Belgian biopharmaceutial company's new anti-seizure drug will slow Cyberonics' patient growth and drag on sales growth.
The new drug, Vimpat, has seen increasing prescriptions since being launched in June, said analyst William Plovanic in a note to analysts Tuesday. Patients are likely to try Vimpat before Cyberonics' VNS therapy system, he said, and those using Vimpat could see a three to six months' delay before doctors prescribe them VNS. New patient growth will be hit, he said.
He downgraded Cyberonics to "Hold" from "Buy."
VNS (vagus nerve stimulation) is used as a secondary therapy to anti-seizure medication for treating epilepsy and other neurological disorders. It will only be prescribed after patients try drugs, Plovanic said.
Plovanic also said the company's management has indicated it will face a higher tax rate in 2010, and he believes that will trigger analysts to cut future earnings estimates. That may weigh on the stock, he said. He cut his price target to $16 from $21.75.
Cyberonics shares dropped $1.05, or 5.9 percent, to $16.79 in afternoon trading.
Tuff-Stuff
15 years ago
CYBX Friday PR~ Cyberonics Provides Update on Depression Post-Approval Study
* Press Release
* Source: Cyberonics, Inc.
* On Friday July 24, 2009, 11:43 am EDT
HOUSTON, July 24 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - News) today announced that the U.S. Food and Drug Administration ("FDA") has approved the company's proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with VNS Therapy(TM).
The company submitted a proposal in November 2008 to reduce the number of study subjects from 460 to 330 and completed enrollment of 331 study subjects in February 2009. With this decision from the FDA, the company expects to complete the follow-up on all patients enrolled in the study by March 2010.
About Cyberonics, Inc. and VNS Therapy(TM)
Cyberonics, Inc. (Nasdaq: CYBX - News) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," and "forecast," or other similar words. Statements contained in this press release are based upon information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information should those facts change or should we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning completing follow-up on patients enrolled in the D-21 clinical study. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 24, 2009.
Contact information
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262
Fax: (281) 218-9332
ir@cyberonics.com
http://finance.yahoo.com/news/Cyberonics-Provides-Update-on-prnews-1191427361.html?x=0&.v=1
Go_Stocks
19 years ago
You sure outsmart eveyone else, make sure you posted on the right board and we are talking about CYBL not CYBX, HAHA:
CYBERLUX CORP (OTC BB:CYBL.OB):
Last Trade: 0.022
Trade Time: May 19
Change: 0.003 (15.79%)
Prev Close: 0.019
Open: 0.023
Bid: 0.021 x 5000
Ask: 0.022 x 5000
Day's Range: 0.016 - 0.024
52wk Range: 0.017 - 0.55
Volume: 4,126,157
Avg Vol (3m): 412,725
Go_Stocks
19 years ago
CYBL NEWS;
Cyberlux Urges Hurricane Preparedness
Company provides lighting options during natural disasters
RESEARCH TRIANGLE PARK, N.C., May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- May 15 - 21 is National Hurricane Preparedness Week, and Cyberlux Corporation urges residents in areas vulnerable to hurricanes to take steps to get ready before the season begins next month.
"There are a number of things people can do to brace for hurricanes," said Mark Schmidt, president and COO of Cyberlux. "Hurricanes can be devastating, but being prepared gives people peace of mind and a sense of control when facing a disaster."
Hurricane Preparedness Tips:
* Develop a family plan for weathering the storm or evacuating
* Identify a safe room or the safest areas in your home for each
hurricane hazard. In certain circumstances the safest areas may not be
your home but within your community
* In the event of an evacuation, map out the nearest evacuation route
* Create a disaster supply kit - bottled water, nonperishable food items,
can opener, supplies of medications, battery-powered radio, charged
cell phone, light source such as a Cyberlux safety lighting product
Cyberlux is a solid-state lighting company that has created breakthrough lighting products for home and industrial use. During power outages and time of critical security lighting needs, the Cyberlux family of products delivers portable, efficient light solutions.
During hurricane season, Cyberlux will introduce two new products that will offer lighting safety, efficiency and flexibility unavailable on the market today:
* The Cyberlux Nightstand Luminary is a lightweight safety light with an
eight inch elliptical reflector, which has three levels of light
brightness. It provides six months of normal use on one set of four AA
batteries.
* Cyberlux will also introduce its Cyclone Power Light Plant this
hurricane season. This portable lighting source is designed to provide
reliable lighting for use in the home or office during electrical
disruptions.
* The Cyclone can be recharged from either a wall outlet or vehicle
charge port. Its rotating light head may be tightly focused for an
intense beam on a work task or adjusted to generate a blanket of light
similar to a table lamp. This product offers 60 hours of light per
charge and provides a port in its handle to recharge a cell phone.
"The Cyclone and Nightstand Luminary products are designed to provide basic lighting needs necessary after disasters such as hurricanes," said Schmidt. "We feel fortunate to have products that can bring a degree of normalcy back to people in the wake of a storm."
In January, Cyberlux donated cases of its lights to tsunami victims and relief workers on the Thai island of Phuket, one of the hardest-hit parts of the mainland. After Hurricane Charley in 2004, Cyberlux donated hundreds of lights to support recovery efforts by emergency management crews during the power outages following the storm's landfall.
About Cyberlux Corporation
Cyberlux Corporation (OTC Bulletin Board: CYBL) has created breakthrough lighting technology that provides the most energy efficient and cost effective lighting solutions available today. Several products are designed to address emergencies such as power outages or critical security lighting needs and others which bring newly developed heatless light into the home for use in closets, cabinet interiors and under cabinet lighting for kitchen counters. Cyberlux uses solid-state semiconductors, trademarked as its diodal(TM) lighting elements, which consume 92 percent less energy than incandescent elements and perform for over 20 years in contrast to 750 hours for traditional bulbs.
For more information, visit http://www.cyberlux.com .
SOURCE Cyberlux Corporation
Register to chat with like-minded investors on our interactive forums.
Penny Roger$
11 years ago
pivotpoint1
11 years ago
Hot Features
Premium
